A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-10-02

AUTHORS

Jill E. Lavigne, Charles Heckler, Jennifer L. Mathews, Oxana Palesh, Jeffrey J. Kirshner, Raymond Lord, Andrew Jacobs, Eric Amos, Gary R. Morrow, Karen Mustian

ABSTRACT

Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300 mg gabapentin versus 900 mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8 weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4 weeks, state anxiety change scores were significantly better for gabapentin 300 and 900 mg (p = 0.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8 weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p < 0.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use. More... »

PAGES

479-486

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10549-012-2251-x

DOI

http://dx.doi.org/10.1007/s10549-012-2251-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1050696961

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23053645


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Anxiety Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anxiety", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclohexanecarboxylic Acids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gabapentin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survivors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "gamma-Aminobutyric Acid", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.417560.1", 
          "name": [
            "Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lavigne", 
        "givenName": "Jill E.", 
        "id": "sg:person.01062636273.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062636273.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.412750.5", 
          "name": [
            "Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heckler", 
        "givenName": "Charles", 
        "id": "sg:person.01051076462.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051076462.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.417560.1", 
          "name": [
            "Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mathews", 
        "givenName": "Jennifer L.", 
        "id": "sg:person.0723160650.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723160650.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Psychiatry, Stanford University Medical School, Palo Alto, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.168010.e", 
          "name": [
            "Department of Psychiatry, Stanford University Medical School, Palo Alto, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palesh", 
        "givenName": "Oxana", 
        "id": "sg:person.01165325062.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165325062.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.412750.5", 
          "name": [
            "Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kirshner", 
        "givenName": "Jeffrey J.", 
        "id": "sg:person.011556615277.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011556615277.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.412750.5", 
          "name": [
            "Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lord", 
        "givenName": "Raymond", 
        "id": "sg:person.01031136534.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031136534.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.412750.5", 
          "name": [
            "Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jacobs", 
        "givenName": "Andrew", 
        "id": "sg:person.01361147022.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361147022.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.417560.1", 
          "name": [
            "Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Amos", 
        "givenName": "Eric", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.412750.5", 
          "name": [
            "Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morrow", 
        "givenName": "Gary R.", 
        "id": "sg:person.01322527467.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322527467.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.412750.5", 
          "name": [
            "Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mustian", 
        "givenName": "Karen", 
        "id": "sg:person.0612440144.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612440144.77"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11764-008-0072-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029624366", 
          "https://doi.org/10.1007/s11764-008-0072-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.2011.3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048031705", 
          "https://doi.org/10.1038/clpt.2011.3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00127-009-0068-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021746171", 
          "https://doi.org/10.1007/s00127-009-0068-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00023210-200822010-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014386251", 
          "https://doi.org/10.2165/00023210-200822010-00003"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-10-02", 
    "datePublishedReg": "2012-10-02", 
    "description": "Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300\u00a0mg gabapentin versus 900\u00a0mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8\u00a0weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4\u00a0weeks, state anxiety change scores were significantly better for gabapentin 300 and 900\u00a0mg (p\u00a0=\u00a00.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8\u00a0weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p\u00a0<\u00a00.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10549-012-2251-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2622650", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693488", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "136"
      }
    ], 
    "keywords": [
      "breast cancer survivors", 
      "hot flashes", 
      "cancer survivors", 
      "gabapentin 300", 
      "alternative therapies", 
      "anxiety symptoms", 
      "double-blinded clinical trial", 
      "use of gabapentin", 
      "clinical trial evidence", 
      "substance use", 
      "breast cancer patients", 
      "single effective treatment", 
      "primary care practices", 
      "high baseline anxiety", 
      "alternative treatment choice", 
      "better treatment outcomes", 
      "treatment of anxiety", 
      "magnitude of improvement", 
      "risk of addiction", 
      "chemotherapy cycles", 
      "neuropathic pain", 
      "trial evidence", 
      "cancer patients", 
      "treatment choice", 
      "clinical trials", 
      "anxiolytic effects", 
      "treatment outcomes", 
      "low dose", 
      "effective treatment", 
      "therapeutic benefit", 
      "gabapentin", 
      "placebo", 
      "analysis of covariance", 
      "similar pharmacology", 
      "patients", 
      "baseline anxiety", 
      "care practices", 
      "anxiety change scores", 
      "change scores", 
      "survivors", 
      "symptoms", 
      "Anxiety Inventory", 
      "current anxiety", 
      "weeks", 
      "pain", 
      "treatment", 
      "therapy", 
      "baseline state anxiety", 
      "benzodiazepines", 
      "anxiety", 
      "baseline", 
      "trials", 
      "state anxiety", 
      "significant interaction", 
      "drug prices", 
      "anxiety traits", 
      "dose", 
      "pharmacology", 
      "efficacy", 
      "outcomes", 
      "scores", 
      "risk", 
      "history", 
      "addiction", 
      "subjects", 
      "use", 
      "abuse", 
      "regression", 
      "ordinary least squares regression", 
      "evidence", 
      "substances", 
      "flashes", 
      "benefits", 
      "effect", 
      "generic drug prices", 
      "analysis", 
      "improvement", 
      "practice", 
      "Inventory", 
      "choice", 
      "scale", 
      "cycle", 
      "covariance", 
      "low cost", 
      "cost", 
      "labels", 
      "interaction", 
      "magnitude", 
      "least squares regression", 
      "squares regression", 
      "traits", 
      "prices", 
      "Speilberger Strait-Trait Anxiety Inventory", 
      "Strait-Trait Anxiety Inventory", 
      "state anxiety change scores", 
      "parsimonious alternative treatment choice"
    ], 
    "name": "A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors", 
    "pagination": "479-486", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1050696961"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10549-012-2251-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23053645"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10549-012-2251-x", 
      "https://app.dimensions.ai/details/publication/pub.1050696961"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_567.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10549-012-2251-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10549-012-2251-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10549-012-2251-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10549-012-2251-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10549-012-2251-x'


 

This table displays all metadata directly associated to this object as RDF triples.

296 TRIPLES      22 PREDICATES      138 URIs      126 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10549-012-2251-x schema:about N15c9a630395a4b8082103525e168e569
2 N1d7316fe420e4ad09d18b2591731adac
3 N49ea6cbaafe144c8ac866ff760b5268d
4 N564a1175b20a49dfa866bd8d66d69fb2
5 N5984e388b6a9402490cb26a361514e74
6 N717fe31d0353484fbf4e1ed2a88c197c
7 N74b06f94411e4b438b3dd1a3d939a84f
8 N81a9c65f00fd44c3ac083da1986e1acc
9 Na14bfb9028274701ba7cab5f7cfecbc0
10 Na505b5535c74439890a3069ac6340390
11 Nf753720fb6804eedb42cf5a33a53b718
12 Nf8d1e68363954a25b937e02a69cc3381
13 anzsrc-for:11
14 anzsrc-for:1112
15 schema:author N96c2843fc46a47c79d4568cf656a7cf5
16 schema:citation sg:pub.10.1007/s00127-009-0068-7
17 sg:pub.10.1007/s11764-008-0072-z
18 sg:pub.10.1038/clpt.2011.3
19 sg:pub.10.2165/00023210-200822010-00003
20 schema:datePublished 2012-10-02
21 schema:datePublishedReg 2012-10-02
22 schema:description Gabapentin is used for the treatment of hot flashes and neuropathic pain in breast cancer survivors, and is commonly used off-label for the treatment of anxiety. Yet, clinical trial evidence to support the use of gabapentin for anxiety symptoms is lacking. In a randomized, double-blinded controlled trial we compared 300 mg gabapentin versus 900 mg gabapentin versus placebo. Subjects were 420 breast cancer patients who had completed all chemotherapy cycles. Anxiety traits and current (state) anxiety were measured using the Speilberger Strait-Trait Anxiety Inventory at baseline, 4 and 8 weeks. Pain was measured at baseline using a 10-point scale. Analyses included analysis of covariance and ordinary least squares regression. At 4 weeks, state anxiety change scores were significantly better for gabapentin 300 and 900 mg (p = 0.005) compared to placebo. The magnitude of improvement was proportional to baseline state anxiety. At 8 weeks, the anxiolytic effects of gabapentin compared to placebo persisted (p < 0.005). We found no significant interactions. The lower dose (300 mg) was associated with the best treatment outcomes for all patients except those with the highest baseline anxiety. Given its similar pharmacology, efficacy in the treatment of hot flashes, and low cost, gabapentin may provide a low cost and parsimonious alternative treatment choice for breast cancer survivors presenting in primary care practices with anxiety symptoms. Gabapentin is effective for hot flashes, and, therefore, may provide therapeutic benefit for both anxiety and hot flashes at a generic drug price. For patients reluctant to take a controlled substance, such as a benzodiazepine, gabapentin may offer an alternative therapy. Similarly, patients with a history of substance use may benefit from gabapentin without risk of addiction or abuse. For cancer survivors experiencing both hot flashes and anxiety, gabapentin may provide a single effective treatment for both and is an alternative therapy for anxiety for patients unwilling to take a benzodiazepine or those with a history of substance use.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree true
26 schema:isPartOf N2bbb9fadf2744475a4ebb039a0df7f40
27 N662bbce08d1047298248fa3b7b6745b9
28 sg:journal.1092777
29 schema:keywords Anxiety Inventory
30 Inventory
31 Speilberger Strait-Trait Anxiety Inventory
32 Strait-Trait Anxiety Inventory
33 abuse
34 addiction
35 alternative therapies
36 alternative treatment choice
37 analysis
38 analysis of covariance
39 anxiety
40 anxiety change scores
41 anxiety symptoms
42 anxiety traits
43 anxiolytic effects
44 baseline
45 baseline anxiety
46 baseline state anxiety
47 benefits
48 benzodiazepines
49 better treatment outcomes
50 breast cancer patients
51 breast cancer survivors
52 cancer patients
53 cancer survivors
54 care practices
55 change scores
56 chemotherapy cycles
57 choice
58 clinical trial evidence
59 clinical trials
60 cost
61 covariance
62 current anxiety
63 cycle
64 dose
65 double-blinded clinical trial
66 drug prices
67 effect
68 effective treatment
69 efficacy
70 evidence
71 flashes
72 gabapentin
73 gabapentin 300
74 generic drug prices
75 high baseline anxiety
76 history
77 hot flashes
78 improvement
79 interaction
80 labels
81 least squares regression
82 low cost
83 low dose
84 magnitude
85 magnitude of improvement
86 neuropathic pain
87 ordinary least squares regression
88 outcomes
89 pain
90 parsimonious alternative treatment choice
91 patients
92 pharmacology
93 placebo
94 practice
95 prices
96 primary care practices
97 regression
98 risk
99 risk of addiction
100 scale
101 scores
102 significant interaction
103 similar pharmacology
104 single effective treatment
105 squares regression
106 state anxiety
107 state anxiety change scores
108 subjects
109 substance use
110 substances
111 survivors
112 symptoms
113 therapeutic benefit
114 therapy
115 traits
116 treatment
117 treatment choice
118 treatment of anxiety
119 treatment outcomes
120 trial evidence
121 trials
122 use
123 use of gabapentin
124 weeks
125 schema:name A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors
126 schema:pagination 479-486
127 schema:productId N0a49258aefed48939ad6ce7b412fdfd6
128 Nc433505988c7419fa5f80cdcd24a5a38
129 Ne43149d3f85a4d55b6bb8e7bef52acff
130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050696961
131 https://doi.org/10.1007/s10549-012-2251-x
132 schema:sdDatePublished 2021-11-01T18:18
133 schema:sdLicense https://scigraph.springernature.com/explorer/license/
134 schema:sdPublisher N636f7700272c42379f81261a8540c56b
135 schema:url https://doi.org/10.1007/s10549-012-2251-x
136 sgo:license sg:explorer/license/
137 sgo:sdDataset articles
138 rdf:type schema:ScholarlyArticle
139 N04e77779fd664bf19d428edce6a096d5 schema:affiliation grid-institutes:grid.417560.1
140 schema:familyName Amos
141 schema:givenName Eric
142 rdf:type schema:Person
143 N0a49258aefed48939ad6ce7b412fdfd6 schema:name doi
144 schema:value 10.1007/s10549-012-2251-x
145 rdf:type schema:PropertyValue
146 N154732fd5b104a8d9ba45256f1681ab8 rdf:first sg:person.0612440144.77
147 rdf:rest rdf:nil
148 N15c9a630395a4b8082103525e168e569 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Middle Aged
150 rdf:type schema:DefinedTerm
151 N1c655f4a43544ee0ab0bd66833b4ddb0 rdf:first sg:person.0723160650.68
152 rdf:rest Nd6ed25a10fb046d5bdd951ab90b0bcb7
153 N1d7316fe420e4ad09d18b2591731adac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Anxiety
155 rdf:type schema:DefinedTerm
156 N1fa17f102bff43459858d0059dde6539 rdf:first sg:person.01322527467.95
157 rdf:rest N154732fd5b104a8d9ba45256f1681ab8
158 N2bbb9fadf2744475a4ebb039a0df7f40 schema:volumeNumber 136
159 rdf:type schema:PublicationVolume
160 N41178fce0e9d42b2bc080d86b788a4a4 rdf:first sg:person.011556615277.91
161 rdf:rest N9a64a712a2394ae69b61925132c234a2
162 N49ea6cbaafe144c8ac866ff760b5268d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Cyclohexanecarboxylic Acids
164 rdf:type schema:DefinedTerm
165 N564a1175b20a49dfa866bd8d66d69fb2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Survivors
167 rdf:type schema:DefinedTerm
168 N5984e388b6a9402490cb26a361514e74 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Breast Neoplasms
170 rdf:type schema:DefinedTerm
171 N5de900c89dc549d1b7d02c5895134cff rdf:first N04e77779fd664bf19d428edce6a096d5
172 rdf:rest N1fa17f102bff43459858d0059dde6539
173 N636f7700272c42379f81261a8540c56b schema:name Springer Nature - SN SciGraph project
174 rdf:type schema:Organization
175 N662bbce08d1047298248fa3b7b6745b9 schema:issueNumber 2
176 rdf:type schema:PublicationIssue
177 N717fe31d0353484fbf4e1ed2a88c197c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Anti-Anxiety Agents
179 rdf:type schema:DefinedTerm
180 N74b06f94411e4b438b3dd1a3d939a84f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Gabapentin
182 rdf:type schema:DefinedTerm
183 N81a9c65f00fd44c3ac083da1986e1acc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Humans
185 rdf:type schema:DefinedTerm
186 N965b860d8bb144d6bc236a80fa5d629f rdf:first sg:person.01051076462.49
187 rdf:rest N1c655f4a43544ee0ab0bd66833b4ddb0
188 N96c2843fc46a47c79d4568cf656a7cf5 rdf:first sg:person.01062636273.82
189 rdf:rest N965b860d8bb144d6bc236a80fa5d629f
190 N9a64a712a2394ae69b61925132c234a2 rdf:first sg:person.01031136534.20
191 rdf:rest Nb3d6fa7f1f534041b340af39e541f8b3
192 Na14bfb9028274701ba7cab5f7cfecbc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Amines
194 rdf:type schema:DefinedTerm
195 Na505b5535c74439890a3069ac6340390 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Treatment Outcome
197 rdf:type schema:DefinedTerm
198 Nb3d6fa7f1f534041b340af39e541f8b3 rdf:first sg:person.01361147022.29
199 rdf:rest N5de900c89dc549d1b7d02c5895134cff
200 Nc433505988c7419fa5f80cdcd24a5a38 schema:name pubmed_id
201 schema:value 23053645
202 rdf:type schema:PropertyValue
203 Nd6ed25a10fb046d5bdd951ab90b0bcb7 rdf:first sg:person.01165325062.34
204 rdf:rest N41178fce0e9d42b2bc080d86b788a4a4
205 Ne43149d3f85a4d55b6bb8e7bef52acff schema:name dimensions_id
206 schema:value pub.1050696961
207 rdf:type schema:PropertyValue
208 Nf753720fb6804eedb42cf5a33a53b718 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name gamma-Aminobutyric Acid
210 rdf:type schema:DefinedTerm
211 Nf8d1e68363954a25b937e02a69cc3381 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Female
213 rdf:type schema:DefinedTerm
214 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
215 schema:name Medical and Health Sciences
216 rdf:type schema:DefinedTerm
217 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
218 schema:name Oncology and Carcinogenesis
219 rdf:type schema:DefinedTerm
220 sg:grant.2622650 http://pending.schema.org/fundedItem sg:pub.10.1007/s10549-012-2251-x
221 rdf:type schema:MonetaryGrant
222 sg:grant.2693488 http://pending.schema.org/fundedItem sg:pub.10.1007/s10549-012-2251-x
223 rdf:type schema:MonetaryGrant
224 sg:journal.1092777 schema:issn 0167-6806
225 1573-7217
226 schema:name Breast Cancer Research and Treatment
227 schema:publisher Springer Nature
228 rdf:type schema:Periodical
229 sg:person.01031136534.20 schema:affiliation grid-institutes:grid.412750.5
230 schema:familyName Lord
231 schema:givenName Raymond
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01031136534.20
233 rdf:type schema:Person
234 sg:person.01051076462.49 schema:affiliation grid-institutes:grid.412750.5
235 schema:familyName Heckler
236 schema:givenName Charles
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051076462.49
238 rdf:type schema:Person
239 sg:person.01062636273.82 schema:affiliation grid-institutes:grid.417560.1
240 schema:familyName Lavigne
241 schema:givenName Jill E.
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062636273.82
243 rdf:type schema:Person
244 sg:person.011556615277.91 schema:affiliation grid-institutes:grid.412750.5
245 schema:familyName Kirshner
246 schema:givenName Jeffrey J.
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011556615277.91
248 rdf:type schema:Person
249 sg:person.01165325062.34 schema:affiliation grid-institutes:grid.168010.e
250 schema:familyName Palesh
251 schema:givenName Oxana
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165325062.34
253 rdf:type schema:Person
254 sg:person.01322527467.95 schema:affiliation grid-institutes:grid.412750.5
255 schema:familyName Morrow
256 schema:givenName Gary R.
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322527467.95
258 rdf:type schema:Person
259 sg:person.01361147022.29 schema:affiliation grid-institutes:grid.412750.5
260 schema:familyName Jacobs
261 schema:givenName Andrew
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361147022.29
263 rdf:type schema:Person
264 sg:person.0612440144.77 schema:affiliation grid-institutes:grid.412750.5
265 schema:familyName Mustian
266 schema:givenName Karen
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612440144.77
268 rdf:type schema:Person
269 sg:person.0723160650.68 schema:affiliation grid-institutes:grid.417560.1
270 schema:familyName Mathews
271 schema:givenName Jennifer L.
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723160650.68
273 rdf:type schema:Person
274 sg:pub.10.1007/s00127-009-0068-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021746171
275 https://doi.org/10.1007/s00127-009-0068-7
276 rdf:type schema:CreativeWork
277 sg:pub.10.1007/s11764-008-0072-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1029624366
278 https://doi.org/10.1007/s11764-008-0072-z
279 rdf:type schema:CreativeWork
280 sg:pub.10.1038/clpt.2011.3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048031705
281 https://doi.org/10.1038/clpt.2011.3
282 rdf:type schema:CreativeWork
283 sg:pub.10.2165/00023210-200822010-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014386251
284 https://doi.org/10.2165/00023210-200822010-00003
285 rdf:type schema:CreativeWork
286 grid-institutes:grid.168010.e schema:alternateName Department of Psychiatry, Stanford University Medical School, Palo Alto, CA, USA
287 schema:name Department of Psychiatry, Stanford University Medical School, Palo Alto, CA, USA
288 rdf:type schema:Organization
289 grid-institutes:grid.412750.5 schema:alternateName Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
290 Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
291 schema:name Community Clinical Oncology Base, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
292 Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
293 rdf:type schema:Organization
294 grid-institutes:grid.417560.1 schema:alternateName Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA
295 schema:name Wegmans School of Pharmacy, St. John Fisher College, 3690 East Avenue, 14618, Rochester, NY, USA
296 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...